Novo Nordisk partnered with Boston startup Vivtex to develop next‑generation oral obesity and diabetes pills. The deal could deliver up to $2.1 billion to the local biotech.

UC Santa Cruz researchers found fishermen's satellite tracks can flag tuna distribution shifts faster than sea‑surface temperatures. That could give fisheries earlier warnings of marine heatwave impacts.

UTSA researchers and maintainers warn AI-generated code is hallucinating package names, creating a predictable new supply-chain attack dubbed “slopsquatting.”

UF researchers retooled tomato carotenoids with a pepper gene, producing orange fruit higher in beta‑carotene that could help address vitamin A deficiency.

Chicago’s Letter AI landed a $40M Series B led by Battery Ventures and launched Letter Compass to bring AI coaching into live deals. The company says it will triple hiring this year.

Mount Sinai‑affiliated clinics in Manhattan are using an FDA‑cleared AI from BrightHeart to flag fetal heart abnormalities, a move studies show boosts detection and shortens review time.

Nobel laureate Richard Axel stepped down as co‑director of Columbia’s Zuckerman Institute after DOJ records linked him to Jeffrey Epstein. Columbia said it found no evidence of legal violations but accepted his resignation.

Forbes will stage its Under 30 Summit in Phoenix April 19–22, highlighting Arizona’s semiconductor, AI and startup momentum and a new local 30 Under 30 list.

Boulder-based Vero Networks closed a $500M growth equity round led by Hamilton Lane, Braemont and Delta‑v to fast‑track fiber builds and acquisitions.

Ubicquia closed a $106M Series D to speed AI for smart‑city sensors and analytics, led by 67 Capital and Marunouchi Innovation Partners.

UW and Princeton simulations map fallout scenarios and show Wisconsin at risk. The work arrives after New START expired on Feb. 5, 2026, renewing arms‑control concerns.

Washington University will add the 162‑year‑old St. Louis College of Pharmacy after the 2026‑27 year, keeping the program at the UHSP campus while approvals proceed.

Massachusetts plans to join the GUARDIAN newborn genome‑screening pilot that tests for 450+ treatable genetic conditions. The voluntary program would require state review before enrollment begins.